Invivyd

Edit info

Founded: 2020

Location: Waltham, MA

Employee range: 50 - 200

Clinical stage: Clin3

Therapy area: COVID-19 prevention

Drug types: INF

Lead product: Adintrevimab

Funding: $356M IPO Aug 2021; $336M C Apr 2021; $80M B Nov 2020; $50M A Jul 2020

invivyd.com

linkedin.com

job board

Drug notes:

Also Clin3 COVID-19 treatment; VYD222 Clin1 COVID-19; VYD224 Clin1 COVID-19; 3 undisclosed programs RD COVID-19, influenza

About:

Invivyd is developing antibody-based therapeutics to treat viral diseases. Each day the cumulative burden of COVID-19 increases case counts, deaths and long COVID-19. Invivyd is working to create safer and higher quality vaccines to reduce societal impact and protect vulnerable populations. Invivyd’s approach is to engineer antibodies designed to match and overcome the challenges of viral evolution and improve vaccine effectiveness. To achieve this, Invivyd is using their discovery platform to explore a vast universe of antibodies beyond the human repertoire and identify antibodies that target parts of the SARS-CoV-2 spike protein. Invivyd’s lead candidate, ADG20, received favorable Phase 3 clinical trial results and is expected to enter the clinic early 2023.